Sign In
Buy IDYA
$30.57
+0.340 (+1.12%)
At Close: Jun 16, 2026
Here's Why IDEAYA Biosciences Lost Nearly 23% Today | The Motley Fool
04:39pm, Thursday, 18'th Jun 2020
The development-stage drug developer is selling common stock to raise cash. It's a wise move.
IDEAYA Announces Pricing of Public Offering of Common Stock
01:34am, Thursday, 18'th Jun 2020
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $15.00 per share, before un
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
12:00am, Thursday, 18'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
Adverum Biotechnologies Inc...
Health Care Flat On Defensive Bias - Health Care Roundup
09:09pm, Wednesday, 17'th Jun 2020Biotech Stock Roundup: REGN Begins Coronavirus Study, VRTX, BIIB Give Updates
01:53pm, Wednesday, 17'th Jun 2020
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bausch Health
The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked
12:00am, Wednesday, 17'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hour.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 16)
ADC Therapeutics SA (NYSE:...
Xconomy: GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance
09:42pm, Tuesday, 16'th Jun 2020
GlaxoSmithKline got its first taste of synthetically lethal cancer therapies via an acquisition. Now it’s trying for a bigger bite of this emerging drug
IDEAYA Announces Proposed Public Offering of Common Stock
08:01pm, Tuesday, 16'th Jun 2020
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering. In addition, IDEAYA intends
Ideaya Biosciences Shares Hit 52-Week High on Partnership With Glaxo | MarketScreener
04:37pm, Tuesday, 16'th Jun 2020GSK pumps $120M into partnership with Ideaya in oncology precision medicine play
03:52pm, Tuesday, 16'th Jun 2020
The California-based company is developing drugs that work through "synthetic lethality," whereby they target two genes at once rather than only targeting one.
P/E Ratio Insights for IDEAYA Biosciences
02:54pm, Tuesday, 16'th Jun 2020
In the current session, IDEAYA Biosciences Inc. (NASDAQ: IDYA) is trading at $12.31, after a 37.60% spike. Over the past month, the stock increased by 58.60%, and in the past year, by 14.66%. With per
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
12:13pm, Tuesday, 16'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) * Applied Molecular Transport Inc (NASDAQ: AMTI) (wen
